VDRM ViaDerma Inc

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial reports.

The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible.

About ViaDerma, Inc.

ViaDerma, Inc. (OTC Expert Market: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: .

Any forecast of future performance is a "forward-looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:

Investor Relations

Email:

Phone: 310-734-6111



EN
04/06/2025

Underlying

VDRMViaDerma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ViaDerma Inc

 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of ...

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes LOS ANGELES, July 16, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, announced today that its  has been posted to the company’s official website, . Due to the company’s current designation on the OTC Markets Expert Market, financial reports are not permitted to be posted directly to the OTC Markets platform. As part of its ongoing commitment to transparency, ViaDerma is making the Annual Report publicly accessible th...

July 16, 2025 1 EN
 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulator...

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a specialty pharmaceutical company, today announced that it remains fully operational and is actively working to complete its overdue annual and quarterly financial reports. The company is not defunct and continues to pursue its business objectives. ViaDerma is currently exploring all strategic options to move the company forward in the most effective manner possible. About ViaDerma, Inc.ViaDerma, Inc. (OTC Expert Mar...

June 4, 2025 1 EN
 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and ...

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India LOS ANGELES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, is pleased to announce the opening of a satellite office in Dubai to facilitate its ongoing expansion in the Middle East. Local regulations require businesses to maintain a physical office within the region to conduct commercial operations, making this a strategic move to further ViaDerma's growth and accessibility in the...

January 21, 2025 1 EN
 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma Announces Significant 2024 Achievements and International Exp...

ViaDerma Announces Significant 2024 Achievements and International Expansion LOS ANGELES, Dec. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, proudly announces the completion of a landmark year marked by significant global expansion and operational milestones. As the company continues its mission to deliver cutting-edge pharmaceutical products to underserved markets, 2024 has proven to be a transformative year. ViaDerma’s expansion efforts in 2024 have led to a remarkable increase in personnel, with...

December 10, 2024 1 EN
 PRESS RELEASE
Free
VDRM VIADERMA INC

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving...

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth LOS ANGELES, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), an innovator in transdermal drug delivery and topical antibiotic products, announced its financial results for the second quarter and six-month period ending June 30, 2024. The company delivered a strong financial performance with notable revenue consistency, positive net income, and a robust increase in cash reserves. Financial Highlights for Q2 2024: Revenue: ViaDerma maintained stead...

October 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch